Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosaleen Lannon

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The New England Journal of Medicine|February 14, 2024
Postmenopausal OsteoporosisDonal Fitzpatrick, Rosaleen Lannon, Kevin McCarroll
The Journal of Clinical Endocrinology and Metabolism|July 15, 2024
Letter to the Editor From Fitzpatrick et al: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than A Single Infusion?"Donal Fitzpatrick, Rosaleen Lannon, Kevin McCarroll
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 9, 2024
Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosisKevin McCarroll, Donal Fitzpatrick, Rosaleen Lannon
The Journal of Clinical Endocrinology and Metabolism|December 11, 2024
Letter to Editor From McCarroll et al: "Approach to the Patient: Normocalcemic Primary Hyperparathyroidism"Kevin McCarroll, Aisling Carroll, Rosaleen Lannon, et al.
Irish Journal of Medical Science|May 21, 2023
Knowledge gap in a cross section of Irish general practitioners prescribing denosumab for osteoporosisEimear O' Reilly, Donal Fitzpatrick, Rosaleen Lannon, et al.
Irish Journal of Psychological Medicine|September 12, 2018
Relapse of postictal psychosis following 14-year symptom-free periodChimdi Uhoegbu, Rosaleen Lannon, Colm Cooney, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 23, 2026
The risk of hypocalcaemia after denosumab administrationAlice Whelan, Finlay Brennan, Rosaleen Lannon, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 5, 2025
Early administration of zoledronic acid after hip fractureKevin McCarroll, James Mahon, Rosaleen Lannon, et al.
Journal of Medical Case Reports|May 29, 2026
Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case reportKevin McCarroll, Aisling Carroll, Finlay Brennan, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 27, 2023
Falsely elevated parathyroid hormone in a patient with osteoporosis: a case report and reviewKevin McCarroll, Donal Fitzpatrick, Margaret McCormack, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The New England Journal of Medicine|February 14, 2024
Postmenopausal OsteoporosisDonal Fitzpatrick, Rosaleen Lannon, Kevin McCarroll
The Journal of Clinical Endocrinology and Metabolism|July 15, 2024
Letter to the Editor From Fitzpatrick et al: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than A Single Infusion?"Donal Fitzpatrick, Rosaleen Lannon, Kevin McCarroll
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 9, 2024
Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosisKevin McCarroll, Donal Fitzpatrick, Rosaleen Lannon
The Journal of Clinical Endocrinology and Metabolism|December 11, 2024
Letter to Editor From McCarroll et al: "Approach to the Patient: Normocalcemic Primary Hyperparathyroidism"Kevin McCarroll, Aisling Carroll, Rosaleen Lannon, et al.
Irish Journal of Medical Science|May 21, 2023
Knowledge gap in a cross section of Irish general practitioners prescribing denosumab for osteoporosisEimear O' Reilly, Donal Fitzpatrick, Rosaleen Lannon, et al.
Irish Journal of Psychological Medicine|September 12, 2018
Relapse of postictal psychosis following 14-year symptom-free periodChimdi Uhoegbu, Rosaleen Lannon, Colm Cooney, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 23, 2026
The risk of hypocalcaemia after denosumab administrationAlice Whelan, Finlay Brennan, Rosaleen Lannon, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 5, 2025
Early administration of zoledronic acid after hip fractureKevin McCarroll, James Mahon, Rosaleen Lannon, et al.
Journal of Medical Case Reports|May 29, 2026
Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case reportKevin McCarroll, Aisling Carroll, Finlay Brennan, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 27, 2023
Falsely elevated parathyroid hormone in a patient with osteoporosis: a case report and reviewKevin McCarroll, Donal Fitzpatrick, Margaret McCormack, et al.
Pageof 2